BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15879497)

  • 1. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer.
    Kristiansen M; Knudsen GP; Maguire P; Margolin S; Pedersen J; Lindblom A; Ørstavik KH
    J Med Genet; 2005 Nov; 42(11):877-80. PubMed ID: 15879497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCoR-L1 variation and breast cancer.
    Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
    Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
    Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.
    Awadelkarim KD; Aceto G; Veschi S; Elhaj A; Morgano A; Mohamedani AA; Eltayeb EA; Abuidris D; Di Gioacchino M; Battista P; Verginelli F; Cama A; Elwali NE; Mariani-Costantini R
    Breast Cancer Res Treat; 2007 Apr; 102(2):189-99. PubMed ID: 17333343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].
    Zhang HT; Lu YF; Zeng J; Lin J; Liao QH; Wan FQ
    Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):480-2. PubMed ID: 17686308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.
    Tilanus-Linthorst MM; Bartels KC; Alves C; Bakri B; Crepin E; van den Ouweland A; Klijn JG; Meijers-Heijboer H; Brekelmans CT
    Breast Cancer Res Treat; 2006 Jan; 95(2):117-23. PubMed ID: 16319990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
    Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
    Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.
    Yazici H; Glendon G; Yazici H; Burnie SJ; Saip P; Buyru F; Bengisu E; Andrulis IL; Dalay N; Ozcelik H
    Hum Mutat; 2002 Jul; 20(1):28-34. PubMed ID: 12112655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
    Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
    Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
    Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
    Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
    Tommasi S; Crapolicchio A; Lacalamita R; Bruno M; Monaco A; Petroni S; Schittulli F; Longo S; Digennaro M; Calistri D; Mangia A; Paradiso A
    Mutat Res; 2005 Oct; 578(1-2):395-405. PubMed ID: 16026807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.